Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-12-21
2009-11-24
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S068000, C546S067000
Reexamination Certificate
active
07622476
ABSTRACT:
This invention relates to 1-allyl ergot alkaloids and their derivatives with selective antagonistic properties to 5-HT2receptors for the prevention of, and relief from, migraine-related headache, Parkinson's disease, disorders of the thrombocyte function, etc.
REFERENCES:
patent: 3113133 (1963-12-01), Hofmann et al.
patent: 4898587 (1990-02-01), Aroonsakul
patent: 6316468 (1999-03-01), Maxey
patent: 5925672 (1999-07-01), Piomelli et al.
patent: 6838461 (2001-02-01), Boettcher
patent: 6218383 (2001-04-01), Bencherif
patent: 3403067 (1985-08-01), None
patent: 2116548 (1983-09-01), None
patent: WO 99/56750 (1999-11-01), None
Marzoni, G. et al.: 6-Methylergoline-8-carboxylic acid esters as serotonin antagonists: N1-substituent effects on 5-HT2 receptor affinity. J. med. Chem. vol. 30, pp. 1823-1826, 1987.
Ingelse, B.A. et al.: Ergot alkaloids as chiral selectors in capillary electrophoresis determination of the separation mechanism. J. of Chromatography A, vol. 755, pp. 251-259, 1996.
Bisceglia, A., Cesarino, F., Cerbo, R., Runge, I., Sorrentino, R., Stocchi, F., Agnoli, A. (1990) Lisuride Prophylactic Treatment of Migraine: A Double-Blind Study at Two Different Dosages New Trends in Clinical Neuropharmacology 1990; vol. IV, N. 4: 35-40.
Somerville, B.W., Herrmann, W.M. (1978), Migraine prophylaxis with lisuride hydrogen maleate—a double blind study of lisuride versus placebo, Headache 1978; 18: 75-79.
Libermann et al., Lisuride in Parkinson's Disease and Related Disorders, in: Lisuride and Other Dopamine Agonists, D.B. Calne, R. Horowski, R. J. McDonald, W. Wuttke (Eds.), Raven-Press, New York, 1983, pp. 419-429.
Rabey et al.; A Long-Term Comparative Study of Lisuride and Levodopa in Parkinson's Disease, in: Parkinsonism and Aging, D. B. Calne et al. (Eds.), Raven-Press, New York, 1989, pp. 261-267.
Glusa, E., Markwardt, F. (1984), Interaction of lisuride with monoamine receptors on human blood platelets, Biochem. Pharmacol. 1984; 33:493-496.
Vinar et al., Antidepressant effects of lisuride are not different from effects of amitriptyline and nortriptyline, Activ. Nerv. Sup. 27, 249-251 (1985).
Bernard L. Bloom, “Behavioral Science”, Community Mental Health Journal (Abstract), vol. 15, No. 3, Sep. 1979.
Munoz RF, Mrazek PJ, Haggery RJ, “Institute of Medicine Report on Prevention of Mental Disorders”—(Abstract),Am. Psychol.Nov. 1996; 51(11): 1130-3.
Akimov GA, “Treatment and Prevention of Diseases of the Nervous System”—(Abstract),Zh Nevropatol Psikhiatr Im SS Korsakova.1967; 67(11): 1652-8.
Stephen D. Silberstein, M.D., Practice Parameter: Evidence-Based Guidelines for Migraine Headache (an Evidence-Based Review),Neurology2000; 55; 754-762.
Alex, KD, Pehek EA, “Pharmacologic Mechanisms of Serotonergic Regulation of Dopamine Neurotransmission”,Pharmacol Ther., Feb. 2007; 113(2): 296-320 (Abstract).
Haugbol S., Pinborg LH, Regeur L, Hansen ES, Bolwig TG, Nielsen FA, Svarer C, Skovgaard LT, Knudsen GM “Cerebral 5-HT2A Receptor Binding is Increased in Patients with Tourette's Syndrom”—Int. J. Neuropsychopharmocol.Apr. 2007; 245-52 (Abstract).
Oh JD, Bibbiani F, Chase TN—“Quetiapine Attenuates Levodopa-induced Motor Complications in Rodent and Primate Parkinsonian Models”—Exp. Neurol.Oct. 2002 177(2): 557-64 (Abstract).
Seroutka SJ—“5-HT Receptors: Past, Present and Future”—Trends Neurosci.Feb. 1995; 18(2): 68-9) (Abstract).
Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG—“The Role of 5-HT2A Receptors in Antipsychotic Activity”—Life Sci.1995; 56(25); 2209-22.
Schmuck K, Ullmer C., Kalkman HO, Probst A, Lubbert H.—“Activation of Meningeal 5-HY2B Receptors: An Early Step in the Generation of Migraine Headache?”—Eur. J. Neurosci.May 1996; 8(5): 959-67.
W.M. Hermann, M. Kristof and M. Sastre y Hernandez—“Preventive Treatment of Migraine Headache With a New Isoergolenyl Derivative”—Journal of International Medical Research(1978) 6. 476.
Brian W. Somerville and Werner M. Herrmann—“Migraine Prophylaxis with Lisuride Hydrogen Maleate—A Double Blind Study of Lisuride Versus Placebo”—Headache18, 2:75-79 (1978).
R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe—“Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation”—The New England Journal of Medicine, Jan. 4, 2007.
A. Avila, X. Cardona, M. Martin-Baranera, P. Maho, F. Sastre and J. Bello—“Does Nefazodone Improve Both Depression and Parkinson Disease? A Pilot Randomized Trial”—Journal of Clinical Psychopharmacology, vol. 23, No. 5, Oct. 2003.
Bryan Roth—“Drugs and Valvular Heart Disease”—The New England Journal of MedicineJan. 23, 2007.
Heike Benes—“Transdermal Lisuride: Short-Term Efficacy and Tolerability Study in Patients with Severe Restless Legs Syndrome”—Sleep Medicine7 (2006) 31-35.
Katrin Bethge, Heinz H Pertz, and Klaus Rehse—“New Oxadiazole Derivatives Showing Party Antiplatelet, Antithrombotic and Serotonin Antagonistic Properties”—Arch. Pharm. Chem. Life Sci.2005, 338, 78-86.
Pau Celada, M. Victoria Puig, Merce Amargos-Bosch, Albert Adell, Francesc Artigas—“The Therapeutic Role of 5HT1Aand 5-HT2AReceptors in Depression”—J. Psychiatry Neurosci.2004; 29(4).
O. Vinar, M. Zapletalek, E. Kazdova, K. Nahunek, J. Molcan—“Antidepressant Effects of Lisuride Are Not Different From Effects of Amitriptyline and Nortriptyline”—Activ. Nerv. Sup.(Praha), 27, 1985 No. 4.
Interaction of Lisuride with Monoamine Receptors on Human Blood Platelets—Biochemical Pharmacology, vol. 33, No. 3, pp. 493-496, 1984.
Cerrito F, et al., 5-HT2-receptors and serotonin release: their role in human platelet aggregation, Life Science 1993; vol. 53, pp. 209-215.
De Angelis L, 5 HT2A antagonists in psychiatric disorders, Current Opinion in Investigational Drugs 2002; vol. 3, pp. 106-112.
De Clerck F, et al., Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
Agents Actions 1982; vol. 12, pp. 388-397.
De Paulis T, M-100907 (Aventis), Current Opinion in Investigational Drugs 2001; vol. 2, pp. 123-132.
Kihara H, et al., AT-1015, a novel serotonin 5-HT2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats, Journal of Cardiovascular Pharmacology 2000; vol. 35, pp. 523-530.
Ninan I, et al., 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion, European Journal of Pharmacology 1998 vol. 358, pp. 111-116.
O'Neil MF, et al., 5-HT2 Receptor Antgonism Reduces Hyperactivity Induced by Amphetamine, Cocaine, and MK-801 But Not D1 Agonist C-APB, Pharmacology, Biochemistry, and Behavior 1999; vol. 63, pp. 237-243.
Sven Jahnichen et al., Institute of Pharmacy, “Agonism at 5-HT2B receptors is not a class effect of the ergolines”, European Journal of Pharmacology 513 (2005) pp. 225-228.
Cvak Jan
Flieger Miroslav
Glusa Erika
Jaenichen Sven
Kranda Karel
Aulakh Charanjit S
Axxonis Pharma AG
Wood Phillips Katz Clark & Mortimer
LandOfFree
Methods of using 1-allyl ergot alkaloid derivatives to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using 1-allyl ergot alkaloid derivatives to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using 1-allyl ergot alkaloid derivatives to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134253